Menu
Search
|

Menu

Close
X

Intellia Therapeutics Inc NTLA.OQ (NASDAQ Stock Exchange Global Market)

28.95 USD
-- (--)
As of Jun 18
chart
Previous Close 28.95
Open --
Volume --
3m Avg Volume 330,473
Today’s High --
Today’s Low --
52 Week High 35.99
52 Week Low 12.43
Shares Outstanding (mil) 43.09
Market Capitalization (mil) 1,180.23
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
26
FY16
16
FY15
6
EPS (USD)
FY18
-0.508
FY17
-1.858
FY16
-1.075
FY15
-0.353
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.18
Price to Sales (TTM)
vs sector
43.12
8.57
Price to Book (MRQ)
vs sector
4.22
4.35
Price to Cash Flow (TTM)
vs sector
--
22.78
Total Debt to Equity (MRQ)
vs sector
0.00
17.37
LT Debt to Equity (MRQ)
vs sector
0.00
12.92
Return on Investment (TTM)
vs sector
-25.93
13.17
Return on Equity (TTM)
vs sector
-30.79
15.15

EXECUTIVE LEADERSHIP

Perry Karsen
Chairman of the Board, Since 2016
Salary: --
Bonus: --
John Leonard
President, Chief Executive Officer, Since 2018
Salary: $300,000.00
Bonus: $123,750.00
Graeme Bell
Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Jose Rivera
Executive Vice President, General Counsel, Since 2017
Salary: $375,000.00
Bonus: $154,688.00
Frank Verwiel
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

40 Erie St Ste 130
CAMBRIDGE   MA   02139-4254

Phone: +1857.2856200

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

SPONSORED STORIES